Showing 901-910 of 5127 results for "".
- Almirall Hosts 16th Skin Academyhttps://practicaldermatology.com/news/Almirall-Hosts-16th-Skin-Academy/2471810/Almirall held the 16th edition of its Skin Academy conference for healthcare professionals in the field of dermatology on March 22-23 at the Barcelona International Convention Center in Spain. The event featured a comprehensive program aimed at sharing state-of-the-art scientific knowledge
- Emrosi Officially Launched for Treatment of Inflammatory Rosaceahttps://practicaldermatology.com/news/emrosi-officially-launched-for-treatment-of-inflammatory-rosacea/2471775/Journey Medical has announced the launch and initial prescriptions for Emrosi for the treatment of inflammatory lesions of rosacea in adults. According to a press release from the manufacturer, the minocycline hydrochloride modi
- Benzene Update at AAD Discusses Both Regulations and Health Riskshttps://practicaldermatology.com/news/Benzene-Update-AAD-Discusses-Both-Regulations-Health-Risks/2471605/Christopher Bunick, MD, PhD, FAAD, made waves at the 2024 American Academy of Dermatology (AAD) Annual Meeting with his presentation about benzene in benzoyl peroxide (BPO) products for acne treatments. At the 2025 AAD Annual Meeting in Orlando, Florida, Dr. Bunick provided an update on the resea
- Analysis: Lower PsA Risk Linked to Psoriasis Treatment Target Achievementhttps://practicaldermatology.com/news/lower-psa-risk-linked-to-psoriasis-treatment-target-achievement/2471577/Patients with psoriasis who achieve the National Psoriasis Foundation (NPF) treatment target after starting biologic therapy may experience a reduced risk of developing psoriatic arthritis (PsA), according to findings from the CorEvitas Psoriasis Registry.
- Promoting Pigmentation and Preventing Relapses Highlighted as Keys in Vitiligo Treatmenthttps://practicaldermatology.com/news/Promoting-Pigmentation-Preventing-Relapses-Highlighted-Keys-Vitiligo-Treatment/2471550/The way practitioners diagnose and manage vitiligo patients continues to advance with recent discoveries in the pathogenesis, risk factors, and features of the disease activity. At the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, one discussion focused on pattern
- Evolving Approaches to Treating Melasma Highlighted at AADhttps://practicaldermatology.com/news/Evolving-Approaches-Treating-Melasma-Highlighted-AAD/2471546/Use of imaging and aggressive treatment are critical in the medical management of melasma in 2025, Mukta Bhardwaj Sachdev,MD, IFAAD, said at the 2025 American Academy of Dermatology (AAD) Annuel Meeting in Orlando, Florida. “You need to use imaging systems, monitor your patients, [use] top
- Get In First: A Derm's Case for Early Psoriasis Treatmenthttps://practicaldermatology.com/news/from-aad-2025-a-case-for-early-psoriasis-treatment/2471544/Addressing psoriasis early in its course may lead to prolonged remission and better outcomes, and dermatologists should take note, according to a presentation at the 2025 American Academy of Dermatology Annual Meeting in Orlando.
- Molluscum Contagiosum: Old Condition, Same Challengeshttps://practicaldermatology.com/news/molluscum-contagiosum-old-condition-same-challenges/2471528/Molluscum contagiosum has been studied and treated for almost two centuries, and while modern therapies are helping patients obtain better outcomes, some aspects of managing and treating the disease remain challenging At the 2025 American Academy of Dermatology (AAD) Annual Meeting, Dr. Ad
- Closing Gaps: Takeda Enhances Diversity in Psoriasis Trialshttps://practicaldermatology.com/news/closing-gaps-takeda-enhances-diversity-in-psoriasis-trials/2471442/Takeda’s phase 3 psoriasis (PsO) clinical trials in the United States achieved success in enhancing racial and ethnic diversity among participants, according to new data from the manufacturer. Psoriasis affects over 7.5 millio
- TSC Reduces Tretinoin-Induced Skin Irritation: Pilot Studyhttps://practicaldermatology.com/news/tsc-reduces-tretinoin-induced-skin-irritation-pilot-study/2471409/A recent pilot study has shown that tetramethylhexadecenyl succinoyl cysteine (TSC) significantly reduces erythema and dryness caused by tretinoin application. These findings may offer a novel approach to minimizing the common adverse effects of tretinoin, potential